For research use only
| Cat No. | ABC-TC0464 |
| Product Type | Human Bladder Cancer Cell Lines |
| Cell Type | Epithelial |
| Species | Human |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Urinary Bladder |
| Disease | Bladder Cancer |
| Product Code | J-82; J 82; J82COT; J82 COT |
Electron microscopic examination did not reveal desmosomes but varying amounts of rough endoplasmic reticulum and prominent microfilaments were observed;
J82 is a human urothelial carcinoma tumor cell line originally established from a poorly differentiated, high-grade (Grade III) transitional cell carcinoma of the urinary bladder from a 58-year-old male patient. It exhibits epithelial-like morphology and grows as adherent monolayers in culture, with a doubling time of approximately 18 ± 5 hours. The line carries mutations in genes such as APC, PIK3CA, and PTEN, contributing to dysregulated signaling relevant to tumor progression. J82 cells display increased chromosomal instability and have been used to study oncogenic pathways, apoptosis resistance, and cell cycle deregulation in bladder carcinoma. They are tumorigenic in immunocompromised models and are suitable for studies of chemoresistance and metastasis mechanisms. The cells undergo rigorous screening and isolation procedures, and are rigorously tested to ensure they are free of contamination from HIV-1, HBV, HCV, Syphilis, Mycoplasma, Fungi, Yeast, and Bacteria.
| Product Code | J-82; J 82; J82COT; J82 COT |
| Species | Human |
| Cat.No | ABC-TC0464 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Urinary Bladder |
| Disease | Bladder Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Bladder Cancer Cell Lines |
J82 cell line is used as an in vitro model of human bladder transitional carcinoma to investigate tumor cell proliferation, apoptosis resistance, cell cycle deregulation, and oncogenic signaling. They support studies in drug sensitivity and resistance assays, molecular pathway analyses, and translational evaluations of anticancer agents relevant to urothelial carcinoma research.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
